All the insights you need in one place.

Case Studies & White Papers

Articles & Press Releases

Rare Disease Therapies and the Case for Outcomes-Based Agreements

READ MORE

Rare Disease Therapies and the Case for Outcomes-Based Agreements

Treatments for rare diseases, such as spinal muscular atrophy or CAR-T therapies like tisagenlecleucel, hold transformative potential for patients. Yet, they often come with significant challenges—uncertainties around long-term efficacy, high costs, and the need for tailored patient selection. Outcomes-Based Agreements (OBAs) offer a structured way to address these challenges, aligning financial risk with therapeutic outcomes. However, their implementation requires careful consideration and planning.

Read More

The Shift to Financially Optimized Clinical Trials

READ MORE

The Shift to Financially Optimized Clinical Trials

As value-based contracting (VBCs) becomes the standard, the role of clinical trials has shifted significantly. They are now essential not only for demonstrating safety and efficacy but also for enhancing financial performance. By creating trials that meet the criteria of VBCs, pharmaceutical companies can increase their financial gains, minimize pricing risks, and facilitate smoother negotiations with payers.

Read More

Clinical Trial Outcomes: The Key to Driving Drug Pricing and Market Access

READ MORE

Clinical Trial Outcomes: The Key to Driving Drug Pricing and Market Access

In value-based contracts (VBCs), clinical trial outcomes are no longer just about proving safety and efficacy—they’re now critical to driving drug pricing and market access strategies. As payers and healthcare systems shift towards outcome-based models, trial data is becoming the foundation for negotiating both price and reimbursement.

Read More

UK: Standardizing the economic evaluation of AI tech

READ MORE

UK: Standardizing the economic evaluation of AI tech

Introduction

Read More

Spain: Reducing unnecessary care and improving HTA education

READ MORE

Spain: Reducing unnecessary care and improving HTA education

Introduction

Read More

Breaking News: Lyfegen Raises Additional CHF 2 Million to Advance Value-Based Healthcare Contracting

READ MORE

Breaking News: Lyfegen Raises Additional CHF 2 Million to Advance Value-Based Healthcare Contracting

Lyfegen HealthTech AG announced today that it has raised CHF 2 million of additional capital, bringing its total funding to CHF 3 million. Read the full press release.

Read More

The Health and Social Consortium of Catalonia to Develop New Value-Based Purchasing Models Incorporating New Tools for Negotiation with the Pharmaceutical Industry

READ MORE

The Health and Social Consortium of Catalonia to Develop New Value-Based Purchasing Models Incorporating New Tools for Negotiation with the Pharmaceutical Industry

The goal of this innovative initiative is to increase the processes of value-based drug procurement, allowing CSC-affiliated health centers to focus on the evaluation of the clinical, economic, and social benefits that the drug can provide in relation to its cost.

Read More

A message from our CEO as Lyfegen Raises $8 Million to Drive Down Drug Costs and Help Patients Access Life-Saving Medications

READ MORE

A message from our CEO as Lyfegen Raises $8 Million to Drive Down Drug Costs and Help Patients Access Life-Saving Medications

 

Read More

Lyfegen und die Schweizerische Krankenversicherung EGK-Gesundheitskasse kooperieren bei der Senkung der Preise für teure Medikamente

READ MORE

Lyfegen und die Schweizerische Krankenversicherung EGK-Gesundheitskasse kooperieren bei der Senkung der Preise für teure Medikamente

Read More

Lyfegen erhält 8 Millionen Dollar, um Arzneimittelpreise zu senken und Patienten den Zugang zu lebensrettenden Medikamenten zu erleichtern

READ MORE

Lyfegen erhält 8 Millionen Dollar, um Arzneimittelpreise zu senken und Patienten den Zugang zu lebensrettenden Medikamenten zu erleichtern

Read More

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

READ MORE

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

We are thrilled to welcome Ina Hasani to our team at Lyfegen as Director of Sales & Business Development for Canada. Ina brings nearly a decade of experience in the life sciences sector, specializing in healthcare strategy, market access, and health economics. We sat down with Ina to learn more about her background, her vision for transforming healthcare in Canada, and what excites her most about joining Lyfegen.

Read More

A Fable of the Blue Bird and Lyfegen's Wise Owls

READ MORE

A Fable of the Blue Bird and Lyfegen's Wise Owls

Once upon a time, In a whimsical forest, there lived a smart and creative blue bird. This bird, known for its brilliance in the world of tiny forest biotech, had concocted a magical potion.

Read More

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Amid the buzz of innovation at Lyfegen, we sat down with Simon, our newest team member, whose journey has brought a fresh...

READ MORE

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Amid the buzz of innovation at Lyfegen, we sat down with Simon, our newest team member, whose journey has brought a fresh perspective to our mission.

Amid the buzz of innovation at Lyfegen, we sat down with Simon, our newest team member, whose journey has brought a fresh...

Read More

Exclusive interview with Girisha Fernando at the launch of Lyfegen’s Value-Based Agreement Library

READ MORE

Exclusive interview with Girisha Fernando at the launch of Lyfegen’s Value-Based Agreement Library

At this years World Evidence, Pricing and Access event, Girisha Fernando, the CEO of Lyfegen, expressed excitement as he spoke about the company’s latest launched offering - the Lyfegen Model & Agreement Library. This unique learning resource is a true game-changer that builds upon the company’s existing product. It expands our horizons by allowing payers and market access & pricing professionals to explore over 2’500 real-life public agreements, and 18 drug pricing models from around the world. The library provides an unparalleled understanding of drug reimbursement models that help users make better informed choices like never before.

Read More

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

READ MORE

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

He’s analytical, a techie and has a fantastic gift for music! Yes, we are talking about the latest addition to our team, our very own “Technical Business Analyst” and Ukrainian superstar: Pavlo Lupandin!

Read More

The Joint Clinical Assessment (JCA): A New Era for Market Access Strategies in the EU

READ MORE

The Joint Clinical Assessment (JCA): A New Era for Market Access Strategies in the EU

The Joint Clinical Assessment (JCA) is poised to fundamentally change how health technologies gain market access across the European Union. Designed to streamline the evaluation process, the JCA promises to bring greater consistency, transparency, and efficiency to how new therapies and medical technologies are assessed for clinical effectiveness. But what does this mean for your market access strategies?

Read More

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

READ MORE

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

We are thrilled to welcome Ina Hasani to our team at Lyfegen as Director of Sales & Business Development for Canada. Ina brings nearly a decade of experience in the life sciences sector, specializing in healthcare strategy, market access, and health economics. We sat down with Ina to learn more about her background, her vision for transforming healthcare in Canada, and what excites her most about joining Lyfegen.

Read More

The Cost of Innovation: Budget Impact of Gene Therapy for Sickle Cell Disease on Medicaid Plans

READ MORE

The Cost of Innovation: Budget Impact of Gene Therapy for Sickle Cell Disease on Medicaid Plans

In December 2023, the U.S. Food and Drug Administration (FDA) approved two groundbreaking gene therapies for sickle cell disease (SCD), offering a new lease on life for individuals battling this severe condition. However, while these therapies bring significant clinical improvements, their cost has emerged as a formidable challenge, particularly for Medicaid, which covers approximately half of the 100,000 individuals in the U.S. with SCD.

Read More

Linking Drug Prices to Success: The Power of Outcome-Based Agreements in the Ozempic Era

READ MORE

Linking Drug Prices to Success: The Power of Outcome-Based Agreements in the Ozempic Era

Outcome-Based Contracts (OBAs) are set to revolutionize access to high-demand medications by linking drug prices to patient outcomes. Specifically, this model ensures that the cost of medication reflects its real-world effectiveness, thereby encouraging better healthcare and sustainable pharmaceutical spending. As outcome-based healthcare gains momentum, OBAs will further push pharmaceutical companies to focus on developing innovative, effective treatments rather than just boosting sales. GLP-1 drugs, such as Wegovy and Ozempic, which are popular for weight loss, could exemplify this shift.

Read More

Study: Out-of-pocket drug costs increasing 5.8% per year

READ MORE

Study: Out-of-pocket drug costs increasing 5.8% per year

A new study investigated how drug rebates affect out-of-pocket costs for health plan beneficiaries. Rebates lower costs for payers, but depending on the health plan, they can raise costs for the patient.  

Read More